Verastem (NASDAQ: VSTM) received a significant boost as BTIG Research upgraded its rating to “strong-buy” in a note to investors on Wednesday, March 5, 2024. This upgrade reflects a growing confidence in the biopharmaceutical company, which specializes in developing treatments for cancer. The positive sentiment comes amidst a series of evaluations from various research firms, indicating a promising outlook for Verastem.
Analyst Ratings and Market Reception
Following BTIG’s upgrade, other firms have also taken a closer look at Verastem’s performance. Jefferies Financial Group reiterated a “buy” rating, establishing a target price of $19.00 for Verastem shares. Meanwhile, HC Wainwright began coverage with a “buy” rating and a target price of $18.00. In another report, Wall Street Zen adjusted its rating from “sell” to “hold,” reflecting a shift in market sentiment. According to MarketBeat.com, the average rating for Verastem now stands at “buy,” with an average price target of $16.83.
Despite the positive ratings, Verastem’s stock experienced a decline of 4.1% recently. The company announced its quarterly earnings on March 4, reporting earnings per share of ($0.50), which fell short of analysts’ expectations of ($0.49). However, revenue for the quarter was reported at $17.54 million, exceeding forecasts of $16.85 million.
Insider Trading and Institutional Investments
In recent insider activity, CEO Dan Paterson sold 10,321 shares of the company on January 12, 2024, at an average price of $7.16, totaling approximately $73,898.36. Following this transaction, Paterson retains 400,104 shares valued at about $2.86 million. CFO Daniel Calkins also sold 5,039 shares on the same day, valued at $36,079.24, resulting in a 4.59% reduction in his holdings.
Over the past ninety days, insiders have sold a total of 17,678 shares, amounting to around $128,685. Currently, insiders own 2.10% of Verastem’s shares, which suggests a cautious approach amid changing market conditions.
Institutional investors have also been active, with Polar Capital Holdings Plc increasing its stake in Verastem by 270.7% during the fourth quarter. This move brought their total holdings to 3,925,126 shares, valued at approximately $30.3 million. Other significant investments include Armistice Capital LLC, which acquired a new stake valued at $8.86 million, and Farallon Capital Management LLC, which invested $15.44 million.
Overall, hedge funds and institutional investors now hold 88.37% of Verastem’s stock, indicating strong institutional confidence in the company’s future.
About Verastem
Founded in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology focuses on the development of small molecule therapies targeting cancer stemness and resistance pathways. The company’s research aims to identify critical signaling nodes that contribute to tumor growth and relapse, particularly in hematologic malignancies and solid tumors. Verastem’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which has shown promise in clinical trials.
As Verastem navigates its financial landscape, the recent upgrades and strong institutional backing may position the company well for future growth, as it continues to innovate in the competitive field of oncology.
